000136930 001__ 136930
000136930 005__ 20240229105107.0
000136930 0247_ $$2doi$$a10.1186/s13063-018-2814-1
000136930 0247_ $$2pmid$$apmid:30107809
000136930 0247_ $$2pmc$$apmc:PMC6092809
000136930 0247_ $$2ISSN$$a1468-6694
000136930 0247_ $$2ISSN$$a1468-6708
000136930 0247_ $$2ISSN$$a1745-6215
000136930 0247_ $$2altmetric$$aaltmetric:46580202
000136930 037__ $$aDKFZ-2018-01367
000136930 041__ $$aeng
000136930 082__ $$a610
000136930 1001_ $$0P:(DE-He78)9abc8949e87d718b8ae755bdc24c4a1e$$aSiegle, Anja$$b0$$eFirst author$$udkfz
000136930 245__ $$aThe Heidelberg Milestones Communication Approach (MCA) for patients with prognosis <12 months: protocol for a mixed-methods study including a randomized controlled trial.
000136930 260__ $$aLondon$$bBioMed Central$$c2018
000136930 3367_ $$2DRIVER$$aarticle
000136930 3367_ $$2DataCite$$aOutput Types/Journal article
000136930 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1535959998_14276
000136930 3367_ $$2BibTeX$$aARTICLE
000136930 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136930 3367_ $$00$$2EndNote$$aJournal Article
000136930 520__ $$aThe care needs of patients with a limited prognosis (<12 months median) are complex and dynamic. Patients and caregivers must cope with many challenges, including physical symptoms and disabilities, uncertainty. and compromised self-efficacy. Healthcare is often characterized by disruptions in the transition between healthcare providers. The Milestones Communication Approach (MCA) is a structured, proactive, interprofessional concept that involves physicians and nurses and is aimed at providing coherent care across the disease trajectory. This study aims to evaluate these aspects of MCA: (1) the training of healthcare professionals, (2) implementation context and outcomes, (3) patient outcomes, and (4) effects on interprofessional collaboration.A multiphase mixed-methods design will be used for the study. A total of 100 patients and 120 healthcare professionals in a specialized oncology hospital will be involved. The training outcomes will be documented using a questionnaire. Implementation context and outcomes will be explored through semi-structured interviews and written questionnaires with healthcare professionals and with the training participants and through a content analysis of patient files. Patient outcomes will be assessed in a pragmatic non-blinded randomized controlled trial and in qualitative interviews with patients and caregivers. Trial outcomes are supportive care needs (SCNS-SF34-G), quality of life (SeiQol and Fact-L), depression and anxiety symptoms (PHQ-4), and distress (Distress Thermometer). Qualitative semi-structured interviews on patients' views will focus on shared decision-making, communication needs, feeling empathy, and further utilization of healthcare services. Interprofessional collaboration will be explored using the UWE-IP-D before the implementation of MCA (t0) and after 3 (t1), 9 (t2), and 12 (t3) months.Using guideline-concordant early palliative care, MCA aims to foster patient-centered communication with shared decision-making and facilitation of advance care planning including end-of-life decisions, thus increasing patient quality of life and decreasing aggressive medical care at the end of life. It is assumed that the communication skills training and interprofessional coaching will improve the communication behavior of healthcare providers and influence team communications and team processes.German Clinical Trials Register, DRKS00013649 and DRKS00013469. Registered on 22 December 2017.
000136930 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136930 588__ $$aDataset connected to CrossRef, PubMed,
000136930 7001_ $$aVillalobos, Matthias$$b1
000136930 7001_ $$aBossert, Jasmin$$b2
000136930 7001_ $$aKrug, Katja$$b3
000136930 7001_ $$0P:(DE-He78)e8557b32dc6950a555b99b119cdd79de$$aHagelskamp, Laura$$b4$$udkfz
000136930 7001_ $$aKrisam, Johannes$$b5
000136930 7001_ $$aHandtke, Violet$$b6
000136930 7001_ $$aDeis, Nicole$$b7
000136930 7001_ $$aJünger, Jana$$b8
000136930 7001_ $$aWensing, Michel$$b9
000136930 7001_ $$aThomas, Michael$$b10
000136930 773__ $$0PERI:(DE-600)2040523-6$$a10.1186/s13063-018-2814-1$$gVol. 19, no. 1, p. 438$$n1$$p438$$tTrials$$v19$$x1745-6215$$y2018
000136930 909CO $$ooai:inrepo02.dkfz.de:136930$$pVDB
000136930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9abc8949e87d718b8ae755bdc24c4a1e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e8557b32dc6950a555b99b119cdd79de$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136930 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136930 9141_ $$y2018
000136930 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRIALS : 2015
000136930 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136930 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136930 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000136930 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000136930 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000136930 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136930 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136930 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136930 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136930 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136930 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136930 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136930 9201_ $$0I:(DE-He78)G835-20160331$$kG835$$lAD Palliative Oncology$$x0
000136930 980__ $$ajournal
000136930 980__ $$aVDB
000136930 980__ $$aI:(DE-He78)G835-20160331
000136930 980__ $$aUNRESTRICTED